# Methylene Blue for Cognitive Dysfunction in Bipolar Disorder

> **NCT00214877** · PHASE3 · COMPLETED · sponsor: **Nova Scotia Health Authority** · enrollment: 40 (estimated)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Methylene Blue

## Key facts

- **NCT ID:** NCT00214877
- **Lead sponsor:** Nova Scotia Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2008-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00214877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00214877, "Methylene Blue for Cognitive Dysfunction in Bipolar Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00214877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*